17-DMAG

17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin; alvespimycin; KOS-1022; NSC 707545) is a semi-synthetic derivative of the benzoquinone ansamycin natural product geldanamycin that binds the N-terminal adenosine triphosphate (ATP) binding pocket of heat shock protein 90 (HSP90) with an IC50 of approximately 24 nanomolar. The compound was developed at the National Cancer Institute (NCI) and by Kosan Biosciences as a water-soluble, orally bioavailable successor to the first-in-class HSP90 inhibitor tanespimycin (17-AAG), from which it is distinguished by the replacement of the C-17 allylamino substituent with a dimethylaminoethylamino group. This substitution confers substantially improved aqueous solubility, reduced hepatic metabolic liability, lower plasma protein binding, and higher oral bioavailability while maintaining or exceeding the antitumor potency of the parent compound in preclinical models. HSP90 is a molecular chaperone essential for the conformational maturation and stabilization of numerous client proteins involved in oncogenic signaling, including HER2/ErbB2, AKT, RAF-1, mutant p53, BCR-ABL, FLT3, KIT, and the inhibitor of nuclear factor kappa-B kinase (IKK) subunits. Binding of 17-DMAG to the HSP90 N-terminal domain displaces the chaperone from its client proteins, targeting them for ubiquitin-proteasome-mediated degradation and simultaneously inducing compensatory heat shock factor 1 (HSF1) activation and upregulation of HSP70 and HSP27 as pharmacodynamic biomarkers of target engagement. The compound preferentially accumulates in tumor tissue relative to normal tissue owing to the higher-affinity, multi-chaperone HSP90 complex conformation present in malignant cells, resulting in a degree of tumor selectivity that is pharmacologically meaningful despite the ubiquitous expression of HSP90 in normal physiology. In preclinical evaluation, 17-DMAG demonstrated broad-spectrum antitumor activity across the NCI 60-cell-line panel (mean GI50 approximately 53 nanomolar) and in xenograft models of melanoma, non-small cell lung cancer, pancreatic cancer, and pediatric solid tumors, with oral and parenteral routes both producing tumor growth inhibition and client protein degradation at tolerated doses. Pharmacokinetic studies in CD2F1 mice and Fischer 344 rats demonstrated wide tissue distribution, linear pharmacokinetics, predominantly hepatobiliary elimination, and quantitatively less extensive metabolism than tanespimycin. Clinical development encompassed four Phase I trials: a weekly intravenous schedule in advanced solid tumors (maximum tolerated dose 80 mg/m2, with dose-limiting hepatic and ocular toxicity at 106 mg/m2 including one treatment-related death); a twice-weekly intravenous schedule in advanced malignancies (recommended Phase 2 dose 24 mg/m2); a twice-weekly schedule in acute myeloid leukemia (AML) demonstrating target inhibition and signs of clinical activity including complete responses in combination with chemotherapy; and a weekly combination with trastuzumab in HER2-positive advanced solid tumors (recommended dose 80 mg/m2 weekly with trastuzumab, with antitumor activity in refractory HER2-positive metastatic breast cancer). A separate Phase I trial in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) demonstrated tolerability without objective responses at the doses studied. Common clinical adverse events included nausea, vomiting, fatigue, hepatic transaminase elevation, and ocular toxicity (blurred vision, dry eye, keratitis). In March 2008, Kosan Biosciences halted clinical development of alvespimycin on the basis of an unfavorable overall toxicity profile relative to the therapeutic window, and the compound has not been advanced to Phase II or Phase III registration trials as a single agent. Subsequent non-oncologic research has characterized 17-DMAG as a neuroprotective agent in rodent models of ischemic stroke and intracerebral hemorrhage, operating through suppression of NF-kappaB-mediated neuroinflammation, reduction of blood-brain barrier disruption, and modulation of the PI3K/Akt signaling pathway via SOX5 targeting. This monograph reviews the chemistry, synthesis, and structural pharmacology of 17-DMAG; the HSP90 chaperone biology and client protein degradation mechanism; the preclinical pharmacology across oncologic and neurologic models; the comprehensive human pharmacokinetic record; the clinical evidence base across all studied indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal; and a structured comparative assessment of five HSP90 inhibitor candidates against 17-DMAG on five competency standards.